Sanofi: Positive results of sarilumab in efficacy, question on the safety
BUY, Fair Value EUR84.5 (+8%)
Sanofi is delivering positive phase III results in efficacy for sarilumab, an anti-IL6 receptor fully-human antibody, developed together with Regeneron in RA (rheumatoid arthritis). Sarilumab is actually very similar to tocilizumab, a drug marketed by the Roche Group under the brand name Actemra.
Full report available to subscribers
Please contact email@example.com